USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth

Participants:

Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Jordan Silberman Dir of Clinical Analytics & ResearchElevance Health
Jordan Silberman
Dir of Clinical Analytics & ResearchElevance Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Arthur Bretonnet Global Digital Innovation LeadUCB Pharma
Arthur Bretonnet
Global Digital Innovation LeadUCB Pharma
Bernhard Kappe Founder & CEOOrthogonal
Bernhard Kappe
Founder & CEOOrthogonal
Celine Ulmann Project ManagementNovartis Institutes for BioMedical Research (NIBR)
Celine Ulmann
Project ManagementNovartis Institutes for BioMedical Research (NIBR)
Gregoire Guillet Chief Business and Value OfficerWeHealth Digital Medicine
Gregoire Guillet
Chief Business and Value OfficerWeHealth Digital Medicine
John Gordon Commercial Lead, International MarketsPfizer
John Gordon
Commercial Lead, International MarketsPfizer
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Krys Zaluski Director, External GrowthBiogen
Krys Zaluski
Director, External GrowthBiogen
Laura Lang Medical Science ManagerKaiku Health
Laura Lang
Medical Science ManagerKaiku Health
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Reginald Swift Founder & CEORubix LS
Reginald Swift
Founder & CEORubix LS

About this Meeting

Commercialization of DTx solutions as digital drug companions seems to be a valuable route to market for DTx companies and a good option for pharma companies, which are still wary of incorporating standalone DTx in their portfolios. However, there are still a lot of questions around the evidence generation for companion DTx. Join us in this informal conversation where we will talk about:   
  •  Level of clinical and economic evidence required - how does this change depending on the stakeholder, mode of action, risk of the product, etc?
  •  Companion DTx and drugs are currently regulated separately; but when it comes to clinical evidence, should DTx - drug be validated together? What are the barriers and challenges to do this? 
  •  Particularities of the study design for companion DTx.  
  •  Role of the DTx company vs. role of pharma in evidence generation  
  •  What is the most efficient way to generate economic evidence?